Ocugen OCGN
NASDAQ OCGN
$1.03 -0.06 (-5.50%)
At close: Sep 30, 2026 · 4:00 PM EDT

Ocugen (OCGN) Current Deferred Revenue (2018)

Updated

Ocugen's Current Deferred Revenue came in at $5 million for Q3 2018, down 33.3% from the prior quarter.

Analysis

Ocugen (OCGN) Current Deferred Revenue (2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 Ocugen 369.56 Mn 186.07 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2018 5.00 Mn
Jun 30, 2018 7.50 Mn
Mar 31, 2018 5.00 Mn
API Access

Ocugen Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=OCGN&period=max&api_key=YOUR_API_KEY